Kinshasa, Democratic Republic of Congo – Nanoviricides, Inc. has received a critically important boost in its quest too combat MPOX, securing authorization from the National Ethics Committee of the Democratic Republic of Congo (DRC) to initiate a phase II clinical trial for its antiviral drug, NV-387.

This trial represents a pivotal step toward potential marketing authorization from the DRC Ministry of Public Health. NV-387 is a broad-spectrum antiviral medication specifically designed to target MPOX disease caused by HMPXV infection.

The Promise of NV-387

The phase II study will primarily evaluate the safety and efficacy of NV-387. The drug has already demonstrated effectiveness against other viruses,including influenza and coronaviruses,in animal models.

Currently, there is no drug that effectively treats HMPXV infection. nanoviricides emphasizes that NV-387 employs a unique mechanism, mimicking host cells to trap and destroy viruses. This innovative approach could revolutionize antiviral treatment.

Clinical Trial Details

The clinical trial will be conducted at the Kinshasa University Hospital, under the guidance of a principal investigator. This initiative addresses the growing demand for more effective antiviral defenses, particularly in light of recent MPOX outbreaks in Africa.

Addressing an Urgent Need

The progress of NV-387 comes at a critical time. The recent MPOX epidemics in Africa have underscored the vulnerability of populations to viral outbreaks and the limitations of current treatment options. The potential approval of NV-387 could provide a much-needed tool in the fight against this disease.